These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 11886510)

  • 1. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
    Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
    J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
    Garbelli S; Mantovani S; Palermo B; Giachino C
    Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
    J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.
    Speeckaert R; van Geel N; Luiten RM; van Gele M; Speeckaert M; Lambert J; Vermaelen K; Tjin EP; Brochez L
    Anticancer Res; 2011 Nov; 31(11):3697-703. PubMed ID: 22110189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.
    Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic implications of autoimmune vitiligo T cells.
    Oyarbide-Valencia K; van den Boorn JG; Denman CJ; Li M; Carlson JM; Hernandez C; Nishimura MI; Das PK; Luiten RM; Le Poole IC
    Autoimmun Rev; 2006 Aug; 5(7):486-92. PubMed ID: 16920575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.
    Steitz J; Brück J; Lenz J; Büchs S; Tüting T
    J Invest Dermatol; 2005 Jan; 124(1):144-50. PubMed ID: 15654968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
    Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
    J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of skin-homing cytotoxic T cells (CD8+ -CLA+) in patients with vitiligo.
    Antelo DP; Filgueira AL; Cunha JM
    Photodermatol Photoimmunol Photomed; 2011 Feb; 27(1):40-4. PubMed ID: 21198882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo.
    Steitz J; Wenzel J; Gaffal E; Tüting T
    Eur J Cell Biol; 2004 Dec; 83(11-12):797-803. PubMed ID: 15679123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N; Gavalas NG; Weetman AP; Kemp EH
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why tyrosinase for treatment of melanoma.
    Song YH
    Lancet; 1997 Jul; 350(9071):82-3. PubMed ID: 9228956
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoimmune aspects of vitiligo.
    Kemp EH; Waterman EA; Weetman AP
    Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
    Mantovani S; Garbelli S; Palermo B; Campanelli R; Brazzelli V; Borroni G; Martinetti M; Benvenuto F; Merlini G; della Cuna GR; Rivoltini L; Giachino C
    J Invest Dermatol; 2003 Aug; 121(2):308-14. PubMed ID: 12880423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells.
    Lin M; Zhang BX; Shen N; Dong XJ; Zhang C; Qi XY; Zhu J; Li YZ; Man MQ; Tu CX
    Eur J Dermatol; 2014; 24(6):676-82. PubMed ID: 25335433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
    Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
    Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.
    Wankowicz-Kalinska A; Mailliard RB; Olson K; Graham F; Edington H; Kirkwood JM; Martinek S; Das PK; Storkus WJ
    Melanoma Res; 2006 Apr; 16(2):165-74. PubMed ID: 16567972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo-like primary melanoma.
    Lugo-Somolinos A; Sánchez JL; Garcia ME
    Am J Dermatopathol; 2008 Oct; 30(5):451-4. PubMed ID: 18806487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.